Leading biotech firm Intas Biopharmaceuticals will invest Rs 160 crore to set up a new drug manufacturing facility at Sanand near Ahmedabad.

The facility, dedicated for Monoclonal Antibodies (MAbs), will undertake large-scale  manufacturing of the recombinant product with a capacity of 5000L in phases.

Intas has signed a Memorandum of Understanding (MoU) with the government of Gujarat for availing special incentives for the project.

Dr. Dhananjay Patankar, Chief Technical Officer, Intas said: “The commercial  production at the proposed MAbs facility is likely to commence by 2011. We have initiated the necessary technical studies for the project."

More From This Section

First Published: Jan 16 2009 | 5:18 PM IST

Next Story